Alerta

METHOD FOR SPECIFIC AND RAPID QUANTIFICATION OF THE TOTAL VIABLE BACTERIAL COUNT IN RAW MILK

Resumen de: US20260276636A1

A method for specifically, rapidly and quantitatively detecting the total viable bacterial count in raw milk, comprises adding a fluorescent probe specific for viable bacteria, a reagent regulating bacterial cell division and a treatment solution to raw milk for a labeling reaction to obtain an initial labeled sample; and detecting particle fluorescent signal in the initial labeled sample using a high-resolution flow cytometer to achieve rapid quantitative detection of the total viable bacterial count; and the total viable bacterial count detected has a good linear correlation with that detected by the traditional plate counting method. The method for rapidly detecting the total viable bacterial count in raw milk can specifically label the viable bacteria in raw milk without being interfered by other biological cells, and the growth activity of the labeled bacteria can be accurately traced to the results of the plate counting method.

항생제 마커가 필요 없는 안정적인 돌연변이를 가진 유전자 변형 박테리아 및 이를 생성하는 시스템 및 방법

Resumen de: WO2025151964A1

One drawback for using attenuated bacteria in cancer therapy and as vaccine vectors faces several challenges. These include ensuring safety and stability of the attenuated strains, achieving consistent colonization or delivery to the target site, and eliciting a controlled immune response. To address this, the present disclosure relates to systems, methods and genetically modified bacteria having reduced risk of reversing virulence without use of antibiotic markers. For example, the genetically modified bacteria comprises a chromosomal disruption in an auxotrophic gene and in one or more gene(s) involved in phosphate regulation, and a DNA rescue molecule comprising a functional copy of the auxotrophic gene. The genetically modified bacteria are obtained from virulent pathogenic bacteria containing a virulence plasmid.

DNA CONSTRUCT FOR EXPRESSING SIGNALING SUBSTANCE FOR CANCER TREATMENT, AND CANCER TREATMENT METHOD USING SAME

Resumen de: EP4806992A1

0001 Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. 0002 Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.

一种抗沙门菌多表位融合蛋白及其制备方法与应用

Resumen de: CN122749776A

本发明公开了一种抗沙门菌多表位融合蛋白及其制备方法和应用。本发明的多表位蛋白及其蛋白作为疫苗SEMV能够同时激活Th1、Th2和Th17型免疫应答，诱导高滴度特异性抗体产生和淋巴细胞增殖，对肠炎沙门菌和鼠伤寒沙门菌均具有交叉保护效力。该蛋白及其制备的疫苗具有安全性高、成分明确、无排毒返强风险等优势，可用于预防禽沙门菌感染。

一种沙门氏菌灭活疫苗的梯度灭活制备方法及其应用

Resumen de: CN122727021A

本发明属于兽用生物制品技术领域，涉及一种沙门氏菌灭活疫苗的梯度灭活制备方法及其应用。该方法包括菌株培养、梯度灭活、灭活检验、抗原浓缩与乳化等步骤，其中梯度灭活包括：第一阶段向菌液中加入终浓度为0.01%～0.10%的甲醛，于2～8℃条件下处理24～72 h；第二阶段补加甲醛至终浓度为0.10%～0.40%，并升温至30～40℃继续处理12～48 h。所述低温低浓度处理用于对菌体表面抗原表位进行预固定，从而减少后续高浓度甲醛处理对抗原结构的破坏。采用本发明方法制备的灭活疫苗在保证灭活彻底性和生物安全性的同时，可显著提高血清抗体水平及肠道黏膜sIgA水平，适用于鸡、鹅等禽类动物沙门氏菌病的预防。

LolCDE PATHWAY INHIBITORS FOR TREATING GRAM-NEGATIVE BACTERIAL INFECTIONS

Resumen de: WO2026187809A2

Provided herein are compounds that target Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and are selective over Gram-negative and Gram-positive commensal bacteria, as well as their methods of use.

MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS

Resumen de: US20260265313A1

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

METHOD AND SYSTEM FOR ENHANCING THE EFFICACY USING IONIZED/AEROSOLIZED HYDROGEN PEROXIDE IN REDUCING MICROBIAL POPULATIONS, METHOD OF USE THEREOF

Resumen de: US20260262663A1

Systems and methods of decontaminating food substances by using cold plasma to enhance the performance of ionized hydrogen peroxide to decontaminate food, and methods of use thereof. Cold plasma activation significantly enhanced the efficacy of hydrogen peroxide mist against bacteria on fresh produce, and the technology may be used to enhance microbial safety. Cold plasma activated ionized hydrogen peroxide (iHP) can be applied on various fresh produce items. In particular, cold plasma enhanced the efficacy of hydrogen peroxide (H2O2) mist against Salmonella.

NOVEL ANTIBODY FOR ANTIMICROBIAL RESISTANCE DETECTION

Resumen de: WO2026185450A1

Novel antibody for antimicrobial resistance detection Antibodies or fragments thereof are provided that specifically bind to bacterial ribosomal subunit S16 and are useful for capturing RNA of a wide-spectrum of bacteria, thereby improving accuracy and speed of antibiotic resistance diagnostics. The antibody or the fragment thereof comprises a heavy-chain variable region CDR1 comprising the amino acid sequence AMS, a heavy-chain variable region CDR2 comprising SEQ ID NO: 16, a heavy-chain variable region CDR3 comprising SEQ ID NO: 18, a light-chain variable region CDR1 comprising SEQ ID NO: 36, a light-chain variable region CDR2 comprising SEQ ID NO: 38 and a light-chain variable region CDR3 comprising SEQ ID NO: 40.

DELIVERY OF PROTEIN EXTRACELLULARLY

Resumen de: US20260263370A1

The described technology pertains to biotechnology, specifically engineered bacterial systems designed for extracellular delivery of therapeutic proteins in cancer treatment. The disclosed bacteria, such as Salmonella typhimurium, are genetically modified to include plasmid coding for a therapeutic protein, a salicylic acid-inducible promoter operably linked to a lysis protein, and a plasmid retention mechanism. These bacteria are modified to remain extracellular by incorporating knockouts such as flhD, which prevent intracellular invasion of cancer cells. Upon induction with salicylic acid, the bacteria lyse and release therapeutic proteins, such as IFNγ, into the tumor microenvironment, converting the environment from immunosuppressive to immunostimulatory and reducing tumor growth. The system is designed to provide safe and tumor-specific delivery, minimizing systemic toxicity. Applications include treating solid tumors, such as pancreatic and breast cancer.

LACTOBACILLUS PLANTARUM HAVING ANTIBACTERIAL EFFECT AND USE THEREOF

Resumen de: WO2026184777A1

A Lactobacillus plantarum strain having an antibacterial effect, and the use thereof, wherein the Lactobacillus plantarum has a deposit number of CGMCC No. 33151. The strain exhibits strong tolerance to bile salts and resists gastric acid, and has good acid producing and H2O2-producing capabilities, has a relatively strong antibacterial effect against common pathogenic bacteria such as Staphylococcus aureus, Candida albicans, Escherichia coli, Salmonella and Helicobacter pylori, and is capable of inhibiting urease activity, interfering with Helicobacter pylori colonization, etc. to inhibit Helicobacter pylori infection or alleviate the symptoms of Helicobacter pylori infection, and reduce the disease severity of colitis in mice. The strain can be used in the preparation of a microbial preparation, and has the potential for use in the preparation of a drug for preventing and/or treating diseases caused by Helicobacter pylori infection.

SALMONELLA-BASED APC-TARGETING DNA VACCINES

Resumen de: WO2026185254A1

The present invention relates to an attenuated Salmonella strain, particularly a Salmonella typhi Ty21a strain comprising a recombinant DNA molecule comprising at least one eukaryotic expression cassette encoding a fusion protein comprising a targeting unit, a multimerization unit, and an antigenic unit and to a pharmaceutical composition comprising said attenuated Salmonella strain, wherein the composition is for oral administration. Said attenuated Salmonella strain or pharmaceutical composition is further provided for use in preventing and/or treating a disorder or disease selected from the group consisting of cancer, an infectious disease a chronic infectious disease or an autoimmune disease.

METHODS AND AGENTS FOR TREATING SOLID TUMOR CANCERS

Resumen de: US20260263534A1

The present disclosure provides a method of treating a solid tumor cancer. The method includes administering a combination to a subject in need thereof. The combination includes at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The present disclosure also provides an anti-tumor agent for use in a method of treating cancer. In such instances, the anti-tumor agent may include the combination.

盐单胞菌内温控启动子的开发与应用

Resumen de: CN122705692A

本发明提供了一种能响应温度变化从而诱导下游基因表达的重组盐单胞菌及其构建方法和应用。所述重组盐单胞菌利用突变筛选得到的Toll/白介素‑1受体类似蛋白A(TIR‑like protein A,TlpA)构建的37°C及42°C诱导型启动子，并且对该37°C及42°C诱导型启动子进行了全面表征。所述重组盐单胞菌可以实现在30°C升温至37°C及37°C升温至42°C时启动目的基因表达的目的，且采用这种方法实现基因的诱导表达，具有操作简单、成本低的特点。

QUORUM SENSING CIRCUIT

Resumen de: WO2026180700A1

The present invention provides a modified quorum sensing circuit, wherein the modified quorum sensing circuit comprises a quorum sensing synthase and a quorum sensing receptor, wherein the quorum sensing synthase and the quorum sensing receptor are transcriptionally separated.

Amanita Muscaria Mushroom Extracts and Products, and Improved Processes for Producing Extracts of Amanita Muscaria Mushrooms at Kilogram Scale

Resumen de: US20260256858A1

0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.

Antibacterial peptide 16253 or derivative thereof, pharmaceutical composition and application

Resumen de: CN122647569A

The invention discloses an antibacterial peptide 16253 or a derivative thereof, a pharmaceutical composition and application, and belongs to the technical field of biology, the amino acid sequence of the antibacterial peptide 16253 is shown as SEQ ID NO: 1 (AAWRKWLGKVLRKAKKYRRIKK), and the antibacterial peptide 16253 has broad-spectrum and efficient antibacterial activity, and can be used for preparing antibacterial peptides. According to the present invention, the prepared Gram-negative bacteria and Gram-positive bacteria have significant inhibition and sterilization effects on Escherichia coli, Pseudomonas, salmonella, streptococcus, Bacillus, Campylobacter and other Gram-negative bacteria and Gram-positive bacteria, do not easily induce the bacteria to produce drug resistance, and have characteristics of extremely low hemolysis, low cytotoxicity and good selectivity index. The invention also provides a derivative and a salt of the antibacterial peptide, a pharmaceutical composition containing the antibacterial peptide, and application of the antibacterial peptide in preparation of antibacterial products or antibacterial drugs, especially application in preparation of drugs for preventing or treating campylobacter infection, and the antibacterial peptide has a wide clinical application prospect.

Enterococcus hirsutei C01, probiotic agent and application of enterococcus hirsutei C01 and probiotic agent

Resumen de: CN122648297A

The invention relates to the technical field of microorganisms, in particular to enterococcus hirsutei C01, a probiotic agent and application of the enterococcus hirsutei C01 and the probiotic agent. The collection number of the enterococcus hiraei C01 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33994. The enterococcus hiraei C01 provided by the invention has the advantages that the collection number is CGMCC No.33994 The bacterial strain has broad-spectrum antibacterial activity, has an inhibiting effect on salmonella enteritidis, salmonella pullorum and salmonella typhimurium, is free of hemolysis, has good stress resistance, can survive in a gastrointestinal environment, also has relatively high biological safety, and can be used for clinically preventing and controlling mixed salmonella infection.

一种生物探针、检测大肠杆菌O157：H7的试纸条及应用

Resumen de: CN122652024A

0001 本发明公开了一种生物探针、检测大肠杆菌O157：H7（ Escherichia coli O157:H7 ）的试纸条及应用。以超声辅助金属离子合成金基纳米合金，采用贻贝化学策略在合金基础上包覆聚多巴胺涂层，最终以AuMnCu@PDA作为信号示踪剂，利用天然贻贝富集的黑色条带和多原子调谐增强的等离子基元，不仅增强了传统的第一比色强度，而且引入了第二光热信号，大大增强了检测灵敏度。比色和光热信号下灵敏度较传统纳米金分别提高了100倍和1000倍，同时具有优异的稳定性和分散性，更有利于构建灵敏、准确的双峰型ICA。这项工作通过简便且绿色的贻贝化学策略为免疫层析测定的信号增强和性能改进开辟了新的途径，为提高分析性能和扩大ICA的实际应用提供了广阔的前景。

血浆中脂磷壁酸（LTA）和/或脂多糖（LPS）阳性细胞外囊泡的用途

Resumen de: CN122651547A

本发明属于医药健康领域，涉及血浆中脂磷壁酸(LTA)和/或脂多糖(LPS)阳性细胞外囊泡在细菌性炎症和/或菌血症的检测中的用途。具体地，本发明提供了一种细菌性炎症和/或菌血症的体外检测方法，包含以下步骤：提供来自受试对象的待测样本；从所述待测样本中分离细胞外囊泡；检测LPS阳性的细胞外囊泡(LPS+EVs)的水平，和/或LTA阳性的细胞外囊泡(LTA+EVs)的水平；如果LPS+EVs和/或LTA+EVs水平增加，则指示所述受试对象存在细菌性炎症和/或菌血症。

K64型肺炎克雷伯菌荚膜多糖单克隆抗体、其杂交瘤细胞株及其应用

Resumen de: CN118620072A

The invention discloses a klebsiella pneumoniae polysaccharide monoclonal antibody, a hybridoma cell strain and application of the klebsiella pneumoniae polysaccharide monoclonal antibody, the sequence information of the klebsiella pneumoniae polysaccharide monoclonal antibody is shown as SEQ NO: 1-SEQ NO: 64, and the preservation numbers of the hybridoma cell strain are respectively CCTCC: C2023296, CCTCC: C2023311, CCTCC: C2023312, CCTCC: C2023313, CCTCC: C2023314, CCTCC: C2023365, CCTCC: C2023366 and CCTCC: C2023367. The klebsiella pneumoniae polysaccharide monoclonal antibody provided by the invention can be specifically combined with capsular polysaccharide of klebsiella pneumoniae, is beneficial to typing of the klebsiella pneumoniae in clinic, and can prove that the klebsiella pneumoniae polysaccharide monoclonal antibody has an excellent effect of preventing and treating K47 type and K64 type klebsiella pneumoniae infection through in-vivo and in-vitro tests of animals; the invention provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has obvious significance for preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value for developing a new generation of klebsiella pneumoniae medicine.

BACTERIOPHAGES, LYTIC AGENTS FOR SALMONELLA SPECIES, COMPOSITIONS, AND METHOD FOR CONTROLLING SALMONELLA SPECIES

Resumen de: US20260248866A1

0000 An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.

BACTERIOPHAGE, COMPOSITION, AND METHOD FOR CONTROLLING BACTERIA OF THE GENUS SALMONELLA

Resumen de: US20260248865A1

0000 A bacteriophage having a wide host range for bacteria of the genus Salmonella is provided. The bacteriophage has bacteriolytic activity against bacteria of the genus Salmonella. The bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence. Methods of using the bacteriophage are also provided.

BACTERIOPHAGE, SALMONELLA BACTERIOLYTIC AGENT, COMPOSITION, AND METHOD FOR CONTROLLING BACTERIA OF THE GENUS SALMONELLA

Resumen de: US20260248139A1

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

Recombinant protein subunit vaccine constructed by combining salmonella flagellin and porcine epidemic diarrhea COE region

Nº publicación: CN122628211A 25/08/2026

Solicitante:

GUANGDONG HAIRUI BIOTECHNOLOGY CO LTD
\u5E7F\u4E1C\u6D77\u9510\u751F\u7269\u6280\u672F\u6709\u9650\u516C\u53F8

Resumen de: CN122628211A

The invention belongs to the technical field of biological medicines, and discloses a recombinant protein subunit vaccine constructed by combining salmonella flagellin and a porcine epidemic diarrhea COE region. The invention specifically discloses a fusion protein, the fusion protein comprises a salmonella flagellin FliCL3A mutant and a PEDV (Porcine Epidemic Diarrhea Virus) structural protein, and the PEDV structural protein is connected to the C end of the salmonella flagellin FliCL3A mutant. A subunit vaccine obtained after emulsification of the fusion protein and an adjuvant provided by the invention can effectively prevent PEDV of a G2b subfamily, start a downstream immune response and induce an organism to generate a series of immune responses, so that a mucosal immune system of the organism generates a large number of PEDV specific antibodies to resist invasion of external pathogens, and a specific immune protection effect is achieved.